Table 1. Treatment protocols aimed at expanding γδ T cells in vivo using zoledronate and IL-2.
| Paper | n | Disease (n) | Patients screened for γδ T cell expansion? | Sub groups within trial (n) | ZOL dose (mg) | IL-2 dose/m2 (MU) | IL2 dose if not by BSA (MU) | Days of IL-2 per cycle | Cycle length (d) | Mean cycles | Lower 95% CI | Upper 95% CI |
| Kunzmann 201237 | 21 | Advanced renal cell carcinoma (7) Multiple myeloma (6) AML (8) |
Yes (21) | 21 | 4 | - | 2 | 6 | 28 | 2.8 | 2.0 | 3.5 |
| Lang 201139 | 12 | Advanced renal cell carcinoma (12) | No (12) | 6 | 4 | 7 | - | 15 | 28 | 3.7 | 0.6 | 6.8 |
| 2 | 4 | 1 | - | 15 | 28 | 17.0 | - | - | ||||
| 1 | 4 | 1–2 | - | 15 | 28 | 3.0 | - | - | ||||
| 2 | 3 | 1 | - | 15 | 28 | 11.5 | - | - | ||||
| 1 | 1.5 | 1 | - | 15 | 28 | 4.0 | - | - | ||||
| Dieli 200740 | 18 | Advanced prostate cancer (18) | No (18) | 9 | 4 | 0 | 0 | 0 | 21 | 9.2 | 5.3 | 13.1 |
| 9 | 4 | - | 0.6 | 1 | 21 | 14.4 | 12.3 | 16.5 | ||||
| Meraviglia 201041 | 10 | Advanced breast cancer (10) | No (10) | 10 | 4 | - | 1 | 1 | 21 | Not specified | ||
Abbreviations: CI, confidence interval; IL-2, interleukin-2; MU, mega unit; ZOL, zoledronate.